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 2 
Abstract 22 
 We differentiated mouse bone marrow cells in the presence of recombinant 23 
macrophage colony stimulating (rM-CSF) factor for 14 days during the flight of space 24 
shuttle Space Transportation System (STS)-126.  We tested the hypothesis that the 25 
receptor expression for M-CSF, c-Fms was reduced.  We used flow cytometry to assess 26 
molecules on cells that were preserved during flight to define the differentiation state of 27 
the developing bone marrow macrophages; including CD11b, CD31, CD44, Ly6C, 28 
Ly6G, F4/80, Mac2, c-Fos as well as c-Fms.  In addition, RNA was preserved during the 29 
flight and was used to perform a gene microarray.  We found that there were significant 30 
differences in the number of macrophages that developed in space compared to 31 
controls maintained on Earth.  We found that there were significant changes in the 32 
distribution of cells that expressed CD11b, CD31, F4/80, Mac2, Ly6C and c-Fos.  33 
However, there were no changes in c-Fms expression and no consistent pattern of 34 
advanced or retarded differentiation during space flight.  We also found a pattern of 35 
transcript levels that would be consistent with a relatively normal differentiation outcome 36 
but increased proliferation by the bone marrow macrophages that were assayed after 37 
14 days of space flight.  There also was a surprising pattern of space flight influence on 38 
genes of the coagulation pathway.  These data confirm that a space flight can have an 39 
impact on the in vitro development of macrophages from mouse bone marrow cells.      40 
41 
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Introduction 42 
 Although the value of the space shuttle has been controversial (Charles, 2011), 43 
one of the accomplishments of the space-shuttle era has been to establish that there 44 
are profound physiological changes during space flight (Chapes, 2004, Charles, 2011, 45 
Fagette et al. , 1999, Harris et al. , 2000, Ronca and Alberts, 2000, Stowe et al. , 2003, 46 
Suda, 1998).  In particular, we have evidence that space flight suppresses 47 
hematopoietic differentiation of macrophages and other blood cells (Ichiki et al. , 1996, 48 
Sonnenfeld et al. , 1992, Sonnenfeld et al. , 1990, Vacek et al. , 1983).  Space flight has 49 
been found to decrease blood monocytes in circulation (Taylor et al. , 1986), induce 50 
monocytes lacking insulin growth factor receptors (Meehan et al. , 1992), and it changes 51 
leukocyte subpopulations in the bone marrow and spleen (Baqai et al. , 2009, Gridley et 52 
al. , 2009, Ortega et al. , 2009, Pecaut et al. , 2003).  Decreases in the expression of the 53 
GM-CSF receptor may explain some of the in vivo physiological changes in 54 
macrophages that have been observed (Kaur et al. , 2005).   55 
 Space flight experiments with rodents also have revealed a diminution in the 56 
percentage and number of early blast cells (CFU-GM) in bone marrow (Sonnenfeld, 57 
Mandel, 1992, Sonnenfeld, Mandel, 1990).  There were also increases in the number of 58 
CD34+ cells in the bone marrow of mice assessed after the flight of STS-108 (Pecaut, 59 
Nelson, 2003).  Skeletal unloading, using antiorthostatic suspension, simulates some of 60 
the physiological changes associated with space flight (Chapes et al. , 1993, Morey-61 
Holton and Globus, 1998, 2002) also diminishes the number of macrophage progenitor 62 
cells in the bone marrow and affects hematopoiesis (Armstrong et al. , 1994, Armstrong 63 
et al. , 1995a, Armstrong et al. , 1993, Dunn et al. , 1983, Dunn et al. , 1985, 64 
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 4 
Sonnenfeld, Mandel, 1992).  Therefore, there are important health issues that might 65 
arise from space flight impacts on hematopoiesis.  66 
 Space flight affects cells by inducing broad physiological changes and/or it can 67 
have direct gravitational impacts on the cells themselves (Todd, 1989).  We previously 68 
addressed the direct impact of space flight on macrophage differentiation at the cellular 69 
level on three different space shuttle flights (Space Transportation System (STS)-57, 60 70 
and 62).  There was increased mouse bone marrow macrophage proliferation and 71 
inhibited differentiation based on changes in expression of MHCII and Mac2 surface 72 
molecules (Armstrong et al. , 1995b).   Because these studies were done at less than 73 
optimal physiological temperatures (22.5° C to 27.0° C), there were some questions 74 
about the impact of these conditions on the outcome.   75 
 During the flight of the space shuttle Endeavour, STS-126, we had an opportunity 76 
to re-examine macrophage growth and differentiation from stem cells at optimal 77 
physiological temperatures (37° C).  This experiment allowed us to assess bone marrow 78 
differentiation in vitro in the absence of the complex in vivo environment.  In particular, 79 
we tested the hypothesis that changes in the receptor for macrophage colony 80 
stimulating factor (M-CSF) may have been responsible for the effects of space flight on 81 
bone marrow macrophage differentiation.  We also had an opportunity to assess global 82 
changes in transcript levels to provide insights about biochemical processes that may 83 
have been perturbed during the differentiation process.    84 
 85 
 86 
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Materials and Methods 88 
Antibodies 89 
Fluorescein isothiocyanate conjugated- (FITC-) anti Ly6C (Clone AL-21), FITC-90 
anti IgM (Clone RA-22), Phycoerythrin conjugated- (PE-) anti CD31 (Clone MEC13.3), 91 
PE- anti IgG2a (Clone R35-95), PE- anti CD44 (Clone IM7), PE- anti IgG2b (Clone A95-92 
1), Allophycocyanin conjugated- (APC-) anti CD3 (Clone 145-2C11), and APC- anti 93 
IgG1 were purchased from BD Pharmingen (San Jose California, CA). Alexa Fluor 647 94 
conjugated-(AF647)– anti Mac2 (Clone eBioM3/38), AF647- anti IgG2a (Clone eBR2a), 95 
PE- anti CD11b (Clone M1-70), PE- anti IgG2b (Clone eB149/0H5), PE- anti Ly6G 96 
(Clone RB6-8C5), PE- anti IgG2b (Clone eB149/0H5), APC- anti F4/80 (Clone BM8), 97 
and APC- anti IgG2a (Clone eBR2a) were purchased from eBioscience Inc. (San Diego, 98 
CA.).  Purified- anti c-Fms (Clone 20), purified – anti IgG, PE- anti IgG, PE- anti c-Fos 99 
(Clone 4) and PE- anti IgG2b (Clone not categorized) were purchased from Santa Cruz 100 
Biotechnology Inc. (Santa Cruz, CA.). 101 
Bone marrow cells and assay set up.  Bone marrow cells were harvested from 102 
humeri, femora, and tibiae of adult C57BL/6 mice (>8-week old; n=21) originally 103 
obtained from the Jackson Laboratory (Bar Harbor, ME) and bred in the animal facility 104 
at Kansas State University (KSU) (Armstrong, Nelson, 1993).  All animal experiments 105 
were approved by Kansas State University Institutional Animal Care and Use 106 
Committee.  Briefly, the bones were recovered and cleaned of all non-osseous tissue.  107 
The marrow cavity was flushed with a sterile PBS solution.  The red blood cells were 108 
lysed by incubating in ammonium chloride lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 109 
and 0.1 mM Na2EDTA, pH 7.3) for 5 min at 4° C.  Pooled cells were centrifuged (300 x 110 
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 6 
g, 5 min) and washed two times with Dulbecco’s Modified Minimal Essentials Medium 111 
(Hyclone Laboratories, Inc., Logan, UT) containing 1% fetal bovine serum, 1% Nu 112 
serum (BD, Bedford, MA), Glutamine plus (2mM, Atlanta Biologicals, Atlanta, GA), 0.1 113 
M HEPES and 10% Opti-MEM (Invitrogen, Grand Island, N.Y.)(DMEM2).  Primary bone 114 
marrow cells were suspended in DMEM2 supplemented with recombinant mouse 115 
macrophage colony stimulating factor (rmM-CSF; 1.5 ug/ml, R & D Systems, 116 
Minneapolis, MN) in preparation for culture in Fluid Processing Apparatus hardware 117 
(FPAs; Figure 1B)(Armstrong, Gerren, 1995b, Hoehn et al. , 2004, Luttges, 1992, 118 
Wilson et al. , 2007).  Briefly, FPAs are 11.70 cm long and 1.35 cm diameter (1.31 mm 119 
glass thickness) glass barrels.  The FPAs have a bypass which allows for the transfer of 120 
media from one chamber to another.  The FPAs were siliconized with Rain-X (Blue 121 
Coral-Slick 50, Ltd; Cleveland, OH) and fitted with a previously siliconized rubber 122 
septum, 1.2 cm from the distal end of the barrel.  Bacti-caps (16-mm diam.; Oxford 123 
Labware, St. Louis, MO) were placed on the proximal end of the FPAs before 124 
sterilization. 125 
 The bone marrow cells were loaded into the primary chamber of 48 FPAs (1 x 126 
107 cells per 3 ml DMEM2 supplemented with rmM-CSF).  A second chamber was 127 
formed by sliding a sterile, siliconized septum parallel to the first septum.  Excess air 128 
was evacuated through a 26GA needle.  DMEM2 supplemented rmM-CSF was loaded 129 
into the second chamber of all 48 FPAs.  A third chamber was formed by adding an 130 
additional septum similarly to the second.  Thirty-two FPAs were loaded with 8% 131 
formalin.  Eight FPAs were loaded with 6.0 M guanidinium isothiocyanate (GITC) 132 
(Woods and Chapes, 1994) and 8 FPAs were loaded with DMEM2 plus rmM-CSF 133 
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 7 
(returned as viable cultures).  The third chambers were sealed with septa as described 134 
above.  The FPAs were transported (day -2 of spaceflight, Figure 1A) at 4oC to the 135 
National Aeronautics and Space Administration (NASA) Space Life Sciences Laboratory 136 
Facility (SLSL) at Kennedy Space Center (KSC).  The FPAs were loaded into 6 Group 137 
Activation Packs (GAPs) (Hoehn, Klaus, 2004), 8 FPAs/GAP.  GAPs were placed into 138 
the Commercial Generic Bioprocessing Apparatus (CGBA) (Hoehn, Klaus, 2004, 139 
Woods and Chapes, 1994)) at 37o C to start incubation.  Parallel temperature and 140 
activation profile conditions were maintained on GAP’s kept at the SLSL. The incubation 141 
was started before the launch of space shuttle (Endeavour) flight Space Transportation 142 
System (STS)-126 (day -1 of spaceflight, Figure 1A).  On day 6 of cell differentiation 143 
(day 5 of spaceflight, Figure 1), 1.5 ml of DMEM2 supplemented with rmM-CSF was 144 
added to the cell suspension by mixing chambers 1 and 2 of the FPAs through the 145 
bypass (Hoehn, Klaus, 2004).  On day 15 of cell differentiation (day 14 of spaceflight) 146 
the content of the FPA’s third chamber was mixed with the cell suspension in the 147 
previously merged chambers.  STS-126 landing occurred in California 17 days after the 148 
start of 37° C cell culture incubation (day 16 of spaceflight).  Samples were placed at 4° 149 
C and transported to SLSL in Florida.  The FPAs were unloaded from GAPs, inspected, 150 
and the cells in medium were collected from 8 FPAs and viable cells (trypan blue 151 
exclusion) were counted on a hemacytometer.  Cell-free media were collected from 152 
these FPA and were frozen and sent to KSU.  Glucose content was measured in each 153 
sample using a digital glucometer (Home Diagnostics, Inc., Ft. Lauderdale, FL).  FPAs 154 
prepared to fix cells in formalin or GITC were transported to KSU at 4° C and were 155 
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 8 
processed 19 days after the cells were place at 37° C to begin differentiation.  Total cell 156 
counts were done on formalin-fixed cells,  157 
Flow cytometry   158 
At KSU, bone marrow cells fixed in formalin were washed in Hank’s Buffered Salt 159 
Solution (HBSS) and counted and cell concentrations were adjusted to 1 x 107 cells per 160 
ml.  Phenotypic analysis of bone marrow-derived cells was performed by fluorescence-161 
activated cell sorting as has been described previously by our group (Ortega, Pecaut, 162 
2009, Potts et al. , 2008).  Five hundred thousand bone marrow cells were blocked with 163 
PBS:goat serum (50:50; 50 μl) at 4o C for 0.5 h.  AF647- anti Mac2 or anti IgG2a (0.5 164 
µg), FITC- anti Ly6C or anti IgM  (0.5 µg), PE- anti CD11b or anti IgG2b (0.1 µg) , APC- 165 
anti CD31 or anti IgG2a (0.5 µg), APC- anti CD3 or anti IgG1 (1 µg), PE- anti Ly6G or 166 
anti IgG2b (0.1 µg), APC- anti F4/80 or anti IgG2a (1.4 µg), PE- anti CD44 or anti IgG2b 167 
(1 µg), purified- anti c-Fms or anti IgG (0.25 µg), and PE- anti c-Fos or anti IgG2b (3.8 168 
µg) were added to the cell suspensions and incubated at 4oC for 1 h.  In some 169 
instances, multiplexing of antibodies with compatible flurochromes was done (e.g. c-Fos 170 
and CD31 or Ly6C and CD31).  The cells were then washed twice in HBSS and 171 
resuspended in HBSS containing 1% formalin.  Cells were analyzed with a 172 
FACSCalibur flow cytometer (Becton Dickson. Rockville, MD) and a minimum of 20,000 173 
events were collected for each sample.   174 
 175 
 176 
 177 
Microarray analysis.   178 
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 9 
At KSU, bone marrow cells preserved in GITC were combined in pools of 2 FPAs 179 
per sample to provide four independent flight and four ground samples for assessment.  180 
RNA was phenol extracted and purified in the aqueous phase using phase-lock tubes 181 
(5-prime, Gaithersburg, MD) centrifuged at 10,000 g for 10 min.  RNA was ethanol 182 
precipitated and DNase treated (Qiagen RNeasy).  Frozen RNA was sent to the 183 
University of Kansas microarray facility at the University of Kansas Medical Center 184 
(Kansas City, KS).  At the facility, RNA concentrations and qualities were analyzed with 185 
an Agilent 2100 Bioanalyzer and RNA 6000 pico assay (Agilent Technologies, Santa 186 
Clara, CA).  Based on RNA quality, the four best RNA samples were selected (Flight A 187 
21.2 ng, RNA Integrity Value (RIN), 3; Flight D 25ng, RIN, 3; Ground B 12.5ng, RIN, 3; 188 
Ground D 24.1 ng, RIN, 3).  All available RNA was concentrated and processed for 189 
target labeling using the 2x IVT labeling protocol.  Briefly, the two round 190 
RNA amplification and labeling procedure was performed using the Affymetrix Small 191 
Sample Labeling Protocol vII (2xIVT) as follows: 50ng of total RNA was primed with T7-192 
oligo(dT) promoter primer (Affymetrix, Santa Clara, CA) and reverse transcribed using 193 
SuperScript Reverse Transcriptase vII kit (Invitrogen).  The first round of RNA 194 
amplification was performed on the cDNA using the MEGAScript T7 Invitro-195 
Transciption kit (Ambion).  Amplified RNA (aRNA) was reverse transcribed using 196 
random primers and SuperScript Reverse Transcriptase vII kit.  The second round RNA 197 
amplification and biotin labeling was conducted using the GeneChip 3' IVT labeling kit 198 
(Affymetrix).  Biotin labeled aRNA was fragmented and hybridized to the GeneChip 199 
Mouse Genome 430 2.0, 3' expression array (Affymetrix) according to manufacturer’s 200 
instructions.  Array washing and staining was conducted using the GeneChip Fluidics 201 
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 10 
Station 450 followed by a 1x scan with the GeneChip 3000 Scanner 7G with Autoloader. 202 
GeneChip processing and data collection was performed using GeneChip Operating 203 
System v1.4 (GCOS).  Probe intensities were consistent amongst the 4 samples and 204 
correlation coefficients among the samples were all greater than 0.95.  205 
 Affymetrix Mouse Genome 430 2.0 CHP files were imported into GeneSpring 206 
GX11 and were transformed to log2 based to create a Flight vs. Ground data 207 
comparison. We performed gene-level analysis with Advanced Workflow with 208 
GeneSpring software. A 50 percentile shift normalization algorithm (Yang et al., 2002) 209 
was applied to the samples. The correlation coefficients within each treatment group 210 
were between 0.9759831 and 0.9926981. The box plot (Figure 2A) of Flight and 211 
Ground groups shows some extreme values above the maximum value in both data 212 
sets. From the Principal Component Analysis plot (Figure 2B), we confirmed some 213 
sample-to-sample variation but there were additional variable differences between Flight 214 
and Ground treatments. ANOVA without Multiple Testing Correction was applied and 215 
1678 significant genes out of 28,972 total genes were selected at a p-value < 0.05 with 216 
up or down gene-level fold changes greater than 1.5 (Figure 2C)(Dudoit et al. , 2002).  217 
To reduce the Type I Error, we performed ANOVA again with the Benjamini Hochberg 218 
FDR of Multiple Testing Correction method with cut-off 0.05 on 1678 genes (Benjamini 219 
and Hochberg, 1995).  We obtained 1678 genes with corrected p-values between 220 
0.00165 and 0.04998.  221 
 The data sets that were uploaded into Ingenuity pathway analysis (IPA) 9.0 222 
software were: 1,678 significant genes with corrected p values < 0.05 and fold changes 223 
> 1.5; 28,972 “all” genes from the Affymetrix array, and 137 genes which were related to 224 
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 11 
cell growth and proliferation.  All input data sets consisted of three data columns, 225 
“Affymetrix Mouse Genome 430 2.0 Array probe ID, p-value, and Fold Change”.  While 226 
running a “Core Analysis” to the dataset, the “Filters and General Settings” were set up 227 
for the analysis.  “Direct” and “Indirect Relationships” were included as interactions and 228 
“endogenous chemicals (metabolites)” in the network analysis, all the data sources 229 
were selected, and “Mouse” as the species.  The IPA result panel included: “Summary, 230 
Networks, Functions, Canonical Pathways, Lists, My Pathways, Molecules, Network 231 
Explorer, and Overlapping Networks”.  We focused on “Networks, Functions, and 232 
Canonical Pathways”. 233 
 Microarray data and the sample-quality data are publicly accessible by creating 234 
an account and logging into www.bioinformatics.kumc.edu/mdms/login.php.  Thereafter 235 
the "Share Data with Users/Groups" link may be used, followed by "Browse through the 236 
shares". The raw data and analyzed data sets may be accessed using the "Bone 237 
Marrow Macrophage Array”.  238 
 239 
Statistical analysis.   240 
Data were evaluated by Student’s t-test or by Chi-Square (χ2) test (Statmost, 241 
Detaxiom Software Inc, Los Angeles, CA).  P-values of <0.05 were selected to indicate 242 
significance.  The data are presented as the mean ± standard deviation (Sd) of the 243 
replicate number.     244 
 245 
Results 246 
Cell growth studies  247 
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In previous work, we found that macrophage growth was enhanced by space 248 
flight.  However, the flight conditions necessitated that the cells differentiated at less 249 
than optimal physiological temperatures (Armstrong, Gerren, 1995b).  To determine if 250 
temperature would impact macrophage growth or differentiation during the STS-126 251 
space flight, we determined cell proliferation in two ways.  Viable cell numbers were 252 
determined at day 17 in the FPA set that was kept in medium throughout the entire 253 
mission and total cell numbers were counted in FPAs that were fixed in formalin at day 254 
14 (Figure 1) of the STS-126 mission.  When we counted cells kept in medium for the 255 
entire mission (nonpreserved), we found that we had more viable cells in the flight FPAs 256 
(3.0 ± 0.6 x 107; mean ± Sd; n=7) compared to the ground (1.7 ± 0.4 x 107; mean ± Sd; 257 
n=4; t-test; p<0.01).  We also found more cells in the formalin-fixed flight FPAs (5.3 ± 258 
0.6 x 106; mean ± Sd; n=28) compared to cell numbers in the FPAs of the ground 259 
controls (4.4 ± 0.6 x 106; mean ± Sd; n=32; t-test; p<0.01).  Although we could not 260 
determine the viability of the fixed cells using the trypan blue exclusion test, the 261 
increase in cell number from the time the cells were fixed on day 14 to recovery on at 262 
day 17 (Figure 1A), suggests that the cells were viable at the time of fixation.  There 263 
also was a similar amount of RNA collected per cell from each of the treatment groups; 264 
4.1 x 10-6 ng/cell.  Therefore, the fixed-cell estimates appear to be accurate and there 265 
appears to be more cell proliferation of the differentiated macrophages in space than on 266 
the ground.  Flight cell numbers increased an average of 5.7 fold and ground cell 267 
numbers increased an average of 3.9 fold from day 14 to day 17.  We also measured 268 
glucose utilization by the cells in the unfixed FPA’s.  We found significantly less (p<0.05, 269 
t-test) glucose usage by flight cells (121±4 mg/dl) compared to cells grown on the 270 
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ground (159±3 mg/dl).  These data suggest that the cells required less energy to 271 
proliferate more in space.   272 
 273 
Assessment of macrophage phenotype after space flight   274 
We found that there was a decrease in MHCII and Mac2 cell surface molecule 275 
expression on bone marrow cells differentiated into macrophages during space flight 276 
(Armstrong, Gerren, 1995b).  In those studies, cells were differentiated at temperatures 277 
ranging from 22.5° C-27.0° C.  We wanted to confirm that the space-flight differences 278 
were not due to the culture temperatures and we wanted to obtain a more 279 
comprehensive phenotypic analysis of the bone marrow-derived, M-CSF-dependent 280 
macrophages that emerged.  We examined the phenotype of the cells using flow 281 
cytometry.  We assigned 4 subpopulations of cells based on size (forward scatter, FSC-282 
H) and granularity (side scatter, SSC-H) (Figure 3A and B).  Region (R) 1 identified the 283 
largest, most granular cells.  R4 represented the smallest, least granular cells in the 284 
differentiated cell population.  The macrophages in R1 and R2 had the highest 285 
expression level of c-Fms, and F4/80 macrophage markers compared to R3 and R4 286 
(e.g. R1+R2 vs. R3+R4: c-Fms, 105.3% vs. 44.7%; F4/80, 6.4% vs. 0.1%; Table 1).  287 
Space flight did not affect these distributions (Table 1).     288 
When we compared the distribution of cells in R1-R4 between space flight 289 
samples and ground controls we had significant differences in the expression in Ly6C, 290 
CD11b, CD31, F4/80, Mac2 and c-Fos (p<0.05, Х2;  Table 1).  There was an overall 291 
decrease in Ly6C, CD11b, and c-Fos expression on cells differentiated in flight 292 
compared to those differentiated on the ground while there was an overall increase in 293 
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CD31, F4/80 and Mac2 in flight cells compared to those differentiated on the ground 294 
(Table 1).   295 
We anticipated that the developing cells would have a macrophage phenotype 296 
after 15 days because the bone marrow cells were differentiated in the presence of 297 
rmM-CSF (Metcalf, 1989).  Therefore, we examined the cells for the concurrent 298 
expression of c-Fms and c-Fos with Mac2 and CD44, Ly6C and Ly6G (Gr-1) with F4/80 299 
to help establish specific macrophage differentiation stages (Table 2).  We found a 300 
significant increase in the overall expression of Mac2+c-Fms+ cells and Mac2+c-Fos+ 301 
cells differentiated in space compared to ground controls (p<0.05) and a significant 302 
change in the distribution between the two treatment groups (p<0.05, χ2 analysis; Table 303 
2).  However, we did not see a difference in the distribution of F4/80+CD44+ cells , 304 
F4/80+Ly6C+ cells or F4/80+Gr-1+ cells (Table 2) between space-flight samples and 305 
ground controls.  306 
 307 
Microarray analysis   308 
To address possible mechanisms of how spaceflight affects macrophage 309 
proliferation and differentiation, we compared the transcriptional profile of bone marrow 310 
cells differentiated during space flight compared to cells differentiated on Earth.  After 311 
14 days of differentiation during space flight, the macrophages were preserved in GITC 312 
and RNA was hybridized to the Affymetrix Mouse Genome 430 2.0 array as described 313 
in the Materials and Methods.  We found that 607 genes had gene transcript levels >1.5 314 
fold higher for flight samples than ground controls.  In contrast, we found that 1071 315 
genes had gene transcript levels >1.5 fold lower than ground controls (p<0.05).  The 316 
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genes were sorted into biological function categories using IPA software (Table 3).  317 
These included genes involved in Carbohydrate metabolism, Cellular development, 318 
Hematopoiesis, Cellullar growth and proliferation, Lipid metabolism and many other 319 
functions (Table 3).    320 
 Since the cells were stimulated with rmM-CSF, we were particularly interested in 321 
transcriptional regulation of genes that are involved in cell division and development 322 
(Assigned to the Cell Death, Hematopoiesis, Cellular Development, Cellular Growth and 323 
Proliferation categories in Table 3).  Using IPA software (www.ingenuity.com), we found 324 
607 unique genes that had significantly higher transcript levels and 1071 unique genes 325 
that had significantly lower transcript levels during space flight compared to ground 326 
controls within the Cell Death, Cellular Growth and Proliferation, Cellular Development 327 
and Hematopoiesis subsets (Table 3).  These genes were further classified based on 328 
gene ontology (GO) annotations (Supplement 1).  In particular, the genes with down 329 
regulated  transcripts encoded enzymes (Lfng, LFNG O-fucosylpeptide 3-beta-N 330 
acetylglucosaminyltransferase; Lipe, lipase, hormone-sensitive; Mettl8, 331 
methyltransferase like 8; and Adcy7 adenylate cyclase 7), growth factors (Pgf, placental 332 
growth factor; Igf1, insulin-like growth factor 1 (somatomedin C); Angpt1, angiopoietin 1; 333 
and Nrg2, neuregulin 2), Transcription factor binding (Meox2, mesenchyme homeobox 334 
2; Mylb1, v-myb myeloblastosis viral oncogene homolog (avian)-like 1; Nab1, NGFI-A 335 
binding protein 1 or EGR1 binding protein 1). The genes that had significantly up 336 
regulated transcripts encoded cytokines (Ccl5; chemokine ligand 5), enzymes (Ido1, 337 
indoleamine 2,3-dioxygenase 1; Nlgn1, neuroligin 1; Hs6st2, heparin sulfate 6-O-338 
sulfotransferase 2); G-protein coupled receptors (Agtr1b, angiotensin II receptor; 339 
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Bdkrb2, bradykinin receptor B2) transporters (Slc7a5, soute carrier family 7; Hba-a1, 340 
hemoglobin, alpha 1, Lrp2, low density lipoprotein receptor-related protein 2).  341 
Molecules assigned to “other" molecule function were further classified according to 342 
MGI GO assignments (Supplement 1).  343 
 Analysis of the effect of space flight on the M-CSF signaling pathway revealed 344 
that gene transcripts encoding for the proteins Csf1r, Etv3, Fos, Rbl-1, Gata1, Gata2, 345 
Myc, Runx1, and E2f4 were downregulated greater than 1.5 fold in cells grown in space 346 
compared to ground controls.  Alternatively, gene transcripts encoding proteins Egr1, 347 
Hoxb4 and Myb were higher in cells grown in space compared to cells maintained on 348 
Earth (Table 4).  However, there were only significant differences (p<0.05) in transcripts 349 
fold change for the genes Csf1r, E2f4, Rbl1, Egr1, Hoxb4, Gata2, Myc and Runx1.   350 
We also classified the gene microarray data into global canonical pathways and 351 
we selected pathways which were associated with genes whose transcription was 352 
significantly affected by the space flight.  Canonical pathways were ranked based on the  353 
–log(p value) scores (p<0.05).  We found that the coagulation system (Table 5), Fc-354 
gamma receptor-mediated phagocytosis in macrophages and monocytes, endoplasmic 355 
reticulum stress, and growth hormone signaling were pathways containing genes which 356 
had transcript levels that were significantly lower in flight samples compared to ground 357 
controls (1.5 fold change, p<0.05; Supplement 2).  The coagulation system had the 358 
highest –log(p value) score of any canonical pathway in this analysis.  There were 6 359 
genes which had significantly lower transcript levels in spaceflight samples compared to 360 
ground controls (p<0.05; Table 5).  In addition, 8 genes showed a trend where transcript 361 
levels were lower than ground controls even though they were not statistically different.  362 
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The insulin receptor signaling pathway also had a high –log(p value) score amongst 363 
canonical signaling pathways identified by the IPA analysis.  Six genes had significantly 364 
lower transcript levels in comparison to ground controls (p<0.05; Table 6).  When we 365 
examined other signaling pathways that are relevant to macrophage function (Oda et al. 366 
, 2004, Raza et al. , 2008), we found that several other macrophage signaling pathways 367 
also had genes that had lower transcript levels in space flight samples compared to 368 
ground controls (p<0.05).  These included Fcγ receptor mediated phagocytosis in 369 
macrophages and monocytes, mTOR, CCR5 signaling, p38 map kinase, and FLT3 370 
signaling in hematopoietic progenitor cells (Supplement 2).  371 
 372 
Discussion 373 
 We reexamined the impact of space flight on macrophage growth and 374 
development during the space flight of STS-126 to test whether changes in the 375 
expression of the receptor for M-CSF were affected by space flight.  We found that bone 376 
marrow-derived macrophages proliferated faster during space flight compared to ground 377 
controls to reaffirm previous findings (Armstrong, Gerren, 1995b) even though there 378 
were significant temperature differences between these experiments and those older 379 
experiments.  The data also support observations that show that bacteria (Benoit and 380 
Klaus, 2007), plant (Matia et al. , 2010) and mammalian cells (Slentz et al. , 2001, Tobin 381 
et al. , 2001) grow faster in space or clinorotation.  The increased proliferation was not 382 
associated with a concomitant increase in glucose use to mediate that growth and 383 
supports the hypothesis that cells do not have to work as hard to grow in space.  384 
However, not all cell types respond in this same manner during space flight.  385 
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Osteoblasts grew less and used less glucose than comparable ground controls on STS-386 
56 (Hughes-Fulford and Lewis, 1996) and U937 cells depleted glucose rapidly when 387 
grown in space hardware (Hatton et al. , 1999).  Therefore, glucose utilization during 388 
growth may be cell-type specific.   389 
 Our primary hypothesis was that the changes in growth and differentiation during 390 
space flight were due to decreased expression of the receptor for M-CSF (c-Fms); the 391 
growth factor used to induce the differentiation of macrophages from bone marrow stem 392 
cells.  We found that the transcript level of Csfr was lower in space flight samples 393 
compared to ground controls.  However, when we examined the level of c-Fms 394 
molecules on the surface of the cells by flow cytometry, we found an increase in the 395 
receptor.  This conundrum could be explained by increased protein translation efficiency 396 
during space flight.  Factors such as protein concentration affect translational efficiency 397 
(Morgan et al. , 1971), and the lack of convection in space could affect local 398 
concentrations of M-CSF as well as other cytokines.  Signal transduction can also be 399 
altered by space flight (Akiyama et al. , 1999, Cogoli, 1997, De Groot et al. , 1991, 400 
Hatton, Gaubert, 1999, Nickerson et al. , 2000, Schwarzenberg, 1999) and the 401 
efficiency of protein synthesis can be altered by cytokines and growth factors and their 402 
coordinating pathways  (Hornberger and Esser, 2004).  However, Etheridge et al. found 403 
that the components that control the RNAi process that regulate translation and the 404 
inhibitory effects of RNAi were unaffected by space flight (Etheridge et al. , 2011).  405 
Therefore, questioning the efficiency of translation may not be appropriate.  406 
Alternatively, the discrepancy between the transcript level and protein level could have 407 
resulted from when we measured these processes.  Csfr transcripts are stabilized 408 
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during macrophage differentiation (Stone et al. , 1990) and c-Fms plasma membrane 409 
levels are generally stable and dependent on the concentration of M-CSF present 410 
(Rettenmier et al. , 1987).  Therefore, the macrophages in our space culture FPAs may 411 
have had more c-Fms molecules present because there was less rmM-CSF remaining 412 
in those FPAs.  Unfortunately, we did not assay for M-CSF in the cultures from this 413 
experiment.  We found very low levels of all the cytokines we did perform assays for 414 
(GM-CSF, IL-1, TNF, IL-6, data not shown).  By 15 days of culture, the supernatants 415 
were generally devoid of labile cytokines.  We also did not have enough RNA left over 416 
after the gene array to validate the Csfr transcript concentrations.  We note, however, 417 
that Runx1 transcript levels were also significantly lower in the space-flown cells.  There 418 
is a strong correlation in expression between Csfr and Runx1, (Himes et al. , 2005) 419 
which helps to increase our confidence in these data.  Nevertheless, additional work will 420 
be needed to resolve this issue.      421 
 The increased number Mac2+c-Fms+ cells and the generally increased 422 
expression of F4/80 on the macrophages differentiated in space suggests that there is a 423 
more differentiated population of cells present after space flight.  F4/80 (Caminschi et al. 424 
, 2001, Hume et al. , 2002) and Mac2 (Dong and Hughes, 1997, Ho and Springer, 1982) 425 
are macrophage-specific markers that tend to increase as macrophages mature 426 
(Leenen et al. , 1994, Leenen et al. , 1990).  A decrease in Ly6C in the total, R1 and R2 427 
populations in the cells we identified would also support this conclusion since Ly6C 428 
identifies myeloid cells at an intermediate stages of differentiation (Leenen, de Bruijn, 429 
1994).  However, other data related to the differentiation state of the macrophages in 430 
our space cultures were not consistent with this conclusion.  We did not see a decrease 431 
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in the Ly6G or CD31 expression on the macrophages flown in space.  Ly6G is 432 
expressed on macrophages early in differentiation, granulocytes and other cells 433 
(Ammon et al. , 2000, Ferret-Bernard et al. , 2004, Leenen, Melis, 1990) and CD31 is 434 
expressed on macrophages early in differentiation and decreases as they mature (de 435 
Bruijn et al. , 1994, de Bruijn et al. , 1998, Watt et al. , 1993).   We also did not see an 436 
increase in CD11b or in the F4/80+Ly6C- or the F4/80+Ly6G- populations.  These latter 437 
two populations should have increased as macrophages became more differentiated.  438 
Therefore, it might be more appropriate to say that the macrophages that develop in 439 
space are different from those that develop on the Earth even though we can not 440 
necessarily characterize them as more or less differentiated from each other.  This 441 
conclusion would not contradict data from STS-57, STS-60 and STS-62 (Armstrong, 442 
Gerren, 1995b).  Moreover, when we assessed the relative levels of transcripts of 443 
transcription factors (Sfpi1, Egr1, Myc, Stat3, Tnf, Hoxb7, Cebpb, Runx1, Chrac1, Egr1, 444 
Irf1, Jun, and Fos) that are necessary for the differentiation of M-CFU  into 445 
macrophages (Valledor et al. , 1998), we found that most of these were not significantly 446 
up or down regulated (>1.5 fold) in the space-flight samples compared to ground 447 
controls.  This suggests that space flight was not affecting the differentiation of the 448 
macrophages. 449 
 There were significant changes in transcript levels of 1678 genes in 450 
macrophages that develop in space compared to those that develop on Earth.  These 451 
data suggest that space flight has an effect on M-CSF-stimulated macrophages in vitro.  452 
The array of gene transcripts that were altered suggests that there were global impacts 453 
on the cells; not just on specific molecular signaling pathways.  Nevertheless, when we 454 
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examined pathways particularly relevant to bone marrow macrophage growth and 455 
differentiation, i.e. the M-CSF signaling pathway, there were transcript changes that 456 
were consistent with increased cellular proliferation.  For example, the down regulation 457 
of Rbl-1 (encodes p107) in the M-CSF pathway in the flight cells is consistent with the 458 
increased proliferation of myeloid cells in p107 knock-out mice (LeCouter et al. , 1998).  459 
Similarly, the significant down regulation of E2f4 would also be consistent with 460 
increased proliferation.  E2f4 regulates the cell cycle and inhibits cell proliferation 461 
(Attwooll et al. , 2004).  Mutations in E2f4 lead to hematological cancers (Komatsu et al. 462 
, 2000) because of its role in regulating cell fate (Enos et al. , 2008).   Furthermore, if 463 
one examines the transcript levels of transcription factors that are activated during the 464 
differentiation of stem cells into M-CFU macrophage progenitors  (Valledor, Borras, 465 
1998), only Hoxb3 and Hoxb4 were up regulated and only Hoxb4  was significant (>1.5 466 
fold increase; p<0.05).  Hoxb3 and Hoxb4 are necessary for myeloid cell proliferation 467 
(Bjornsson et al. , 2003, Sauvageau et al. , 1997) but are not needed for lineage 468 
commitment (Bjornsson, Larsson, 2003).  In contrast, two of the three transcription 469 
factors that are significantly down regulated during early macrophage differentiation in 470 
space flight samples (Gata2 and Runx1) are either not needed for macrophage terminal 471 
differentiation (Gata2) (Tsai and Orkin, 1997) or serve as an inhibitor of proliferation 472 
(Runx1) (Himes, Cronau, 2005).  Interestingly, Myc was also down regulated and 473 
macrophage proliferation is also driven by c-Myc protein (Wickstrom et al. , 1988, Yu et 474 
al. , 2005).  This inconsistency might be because c-Myc is needed early in macrophage 475 
proliferative response during differentiation (Valledor, Borras, 1998) and we were 476 
already 15 days into the differentiation process.  This hypothesis is supported by data 477 
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showing that transcripts of other key inducers of proliferation such as cyclophilin A 478 
(Ppia) and cyclin-dependent kinase (Cdk2) also trended lower in space-flight samples 479 
(Ppia, -1.11 fold change; Cdk2, -1.26 fold change) and cyclin-dependent kinase inhibitor 480 
(Cdkn1a), an inhibitor of cellular proliferation trended with higher transcript levels in 481 
space-flight cells (Cdkn2a,  -1.32 fold change).  It appears that the proliferative phase 482 
was in the process of changing by the 15th day of culture.   483 
 The most interesting revelation of the IPA analysis of the transcriptional array of 484 
bone marrow macrophage differentiation in space was the broad impact of space flight 485 
on the coagulation pathway.  Sixteen genes were down regulated in toto.  Genes 486 
encoding proteins involved in both the intrinsic and extrinsic pathways were affected; 487 
indicating a broad impact.  Kimzey et al. suggested that there may be a 488 
“hypercoagulative condition”  after the flight of the Skylab astronauts (Kimzey et al. , 489 
1975b).  However, after closer examination of the data from Skylab missions (Kimzey, 490 
1977, Kimzey et al. , 1975a, Kimzey et al. , 1976, Kimzey, Ritzmann, 1975b), it appears 491 
that this hypothesis was based on observations of platelets and not coagulation-492 
pathway proteins.  If there are alterations in the ability of space travelers to coagulate 493 
blood, this could have ramifications on astronaut recovery from injury from bleeding, 494 
angiogenesis and inflammation.  For example, fragments of plasminogen (encoded by 495 
Plg), which had significantly lower transcript concentrations in flight samples compared 496 
to ground controls, inhibit angiogenesis (O'Reilly et al. , 1994) and are involved in 497 
regulating macrophage migration (Gong et al. , 2008).  Additional examination of these 498 
systems in vivo is justified.  499 
 500 
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 501 
 502 
Conclusion 503 
We have confirmed that space flight has a significant impact on murine bone 504 
marrow macrophages in vitro.  We see significant increases in cell proliferation and 505 
changes in the pattern of expression of cell-surface differentiation antigens.  Differences 506 
in gene expression in 1,678 genes in the differentiating macrophages during space flight 507 
are consistent with this observation.  Importantly, these changes do not appear to be 508 
from decreases in the surface expression of the receptor for M-CSF.  We recently found 509 
that there are changes in bone marrow subpopulations in mice after they are subjected 510 
to space flight (Ortega, Pecaut, 2009).  The data from STS-126 indicates that there can 511 
also be direct gravitational effects on those bone marrow cells.  The long-term effects of 512 
these changes have yet to be determined and should be the focus of appropriate 513 
studies on the International Space Station.   514 
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Figure Legends 532 
 533 
Figure 1.  A.  Time-line of activities for bone marrow macrophage differentiation on STS-534 
126.  B.  Fluid Processing Apparatus (FPA).  3.0 ml of cells were placed in a chamber 1 535 
separated by two rubber septa.  The FPA is engineered with a bypass so that when the 536 
internal assembly of septa and biological samples are pushed to the left the medium in 537 
the second chamber will mix with the material in chamber 1 and septa 2 and 3 will 538 
compress.  Septa 3 and 4 also compress with additional movement to mix the contents 539 
of chamber 3 with the contents previously mixed.    540 
 541 
Figure 2.  Analyses of data from microarray.  (A)  The box plot of gene expression Flight 542 
and Ground control groups. (B) Principal component analysis of Flight and Ground 543 
treatments.  (C)  Volcano plot of Flight sample transcript levels that are significantly 544 
different from Ground control samples.  Dark dots represent genes that have >1.5 fold-545 
change (x-axis) as well as high statistical significance cut off with a p-value < 0.05 (y-546 
axis). The gray dots represent genes that are not significantly different.   547 
 548 
Figure 3.  Flow cytometric analysis of Flight (left column) and Ground control (right 549 
column) samples.  (A and B) Representative plots of forward vs. side scatter to 550 
establish Regions 1-4 for further analysis.  Histograms of total cells (C and D), Region 1 551 
(E and F), Region 2 (G and H), Region 3 (I and J), Region 4 (K and L) for c-Fms 552 
expression.    553 
 554 
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Table 1. Effect of spaceflight on M-CSF differentiated bone 
marrow-derived cell phenotypic markers. 
Cell marker Subpopulation Spaceflight 
Ground 
control 
Ly6C* Total cells 5.8a 9.2 
 
R1 20.0 24.7 
 
R2 2.9 4.5 
 
R3 0.5 7.1 
 
R4 1.1 4.7 
c-Fms Total cells 34.8 30.3 
 
R1 77.4 67.9 
 
R2 56.2 37.4 
 
R3 45.0 35.3 
 
R4 10.5 9.4 
CD11b* Total cells 0.1 6.7 
 
R1 1.2 1.4 
 
R2 0 7.8 
 
R3 0 57.3 
 
R4 0 49.9 
CD44 Total cells 45.4 45.7 
 
R1 62.7 67.0 
 
R2 23.9 31.8 
 
R3 16.3 16.8 
 
R4 6.0 3.4 
CD31 
(PECAM)* Total cells 4.8 3.2 
 
R1 3.8 2.8 
 
R2 14.2 4.1 
 
R3 19.0 4.5 
 
R4 13.3 15.1 
Ly6G (Gr-1) Total cells 32.6 30.0 
 
R1 39.7 41.0 
 
R2 11.5 8.4 
 
R3 6.6 8.9 
 
R4 4.3 8.4 
CD3 Total cells 0.4 0 
 
R1 0.1 0 
 
R2 2.2 0 
 
R3 0.8 0 
 
R4 1.5 0 
F4/80* Total cells 5.0 2.7 
 
R1 11.6 3.7 
 
R2 10.4 5.2 
 
R3 1.4 0.1 
 
R4 1.0 0.0 
Mac2* Total cells 5.5 4.5 
 
R1 8.5 0.5 
 
R2 8.6 0 
 
R3 6.2 0.4 
 
R4 4.7 0.6 
c-Fos* Total cells 2.5 3.3 
 
R1 3.7 4.0 
 
R2 8.0 3.6 
Table
 
R3 10.6 0 
 
R4 7.7 0 
Numbers indicate % of cells above isotype control staining; 
20,000 cells analyzed per sample. R1, region 1; R2, region 2; 
R3 region 3; R4, region 4. * Indicates flight sample is 
distributed differently from ground control as assessed by χ2 
analysis. 
 
Table 2. Effect of spaceflight on expression of double positive cell 
surface markers of differentiated bone marrow derived cells. 
Cell marker Subpopulation a Spaceflight b Ground 
control b 
Mac2+, c-Fms+ c Total cells 15.9 1.7 
 R1 12.7 3.6 
 R2 27.0 0 
 R3 19.3 1.3 
 R4 12.3 1.3 
Mac2+, c-Fos+ c Total cells 6.8 0 
 R1 8.4 0.1 
 R2 24.9 0 
 R3 13.4 0 
 R4 1.5 0 
F4/80+, CD44+ Total cells 3.1 3.2 
 R1 5.8 5.7 
 R2 3.8 0 
 R3 0.5 1.3 
 R4 0.7 0.1 
F4/80+, Ly6C+ Total cells 0.3 0.1 
 R1 0.4 5.0 
 R2 0.5 1.4 
 R3 0.2 0.5 
 R4 0.1 0.3 
F4/80+, Gr1+ Total cells 0.5 0 
 R1 0.8 3.2 
 R2 0.4 0.9 
 R3 0.1 0.1 
 R4 0 0 
a Subpopulations established with forward vs. side scatter dot plots. 
R1, region 1; R2, region 2; R3 region 3; R4, region 4 
b Numbers indicate % cells above isotype control staining; 20,000 
cells analyzed per sample.  
c Indicates flight sample is distributed differently from ground control 
as assessed by χ2 analysis. 
 
 
Table
Table 3. Biologic function classification of bone marrow derived macrophages gene regulation 
due to spaceflight 
Biological function categoriesa 
Lower 
p-valueb 
(x 10-6) 
Upper 
p-valueb 
(x 10-6) 
Number of 
genes 
Number of 
genes 
upregulate
dc 
Number of 
genes 
downregulated
c 
Inflammatory Response 0.34 46300 100 32 68 
Carbohydrate Metabolism 46.8 44300 44 6 38 
Molecular Transport 56.7 44300 82 19 63 
Small Molecule Biochemistry 56.7 44300 102 21 81 
Cell Death 64.5 47300 81 21 60 
Hematological System Development 
and Function 
87.9 
47700 118 38 80 
Hematopoiesis 87.9 47900 76 23 53 
Organismal Development 87.9 43200 72 22 50 
Tissue Development 87.9 46300 108 37 71 
Cellular Compromise 212 46100 43 14 29 
Cardiovascular System Development 
and Function 
239 
43200 79 25 54 
Cellular Development 245 47900 141 39 103 
Cellular Growth and Proliferation 378 47300 137 45 92 
Humoral Immune Response 378 39600 43 11 32 
Organismal Survival 385 7710 56 18 38 
Developmental Disorder 591 21300 17 1 16 
Genetic Disorder 591 21300 34 8 26 
Metabolic Disease 591 23200 16 1 15 
Cell-To-Cell Signaling and Interaction 654 46100 60 17 43 
Gastrointestinal Disease 671 28000 20 6 14 
Inflammatory Disease 671 35700 17 7 10 
Cellular Movement 701 47700 96 27 69 
Table
Immune Cell Trafficking 701 47700 65 18 47 
Embryonic Development 824 37600 39 9 30 
Lipid Metabolism 824 44300 72 12 60 
Cell Cycle 949 42500 23 8 15 
Antimicrobial Response 959 21400 12 3 9 
Hematological Disease 1170 34800 32 11 21 
Organ Development 1240 39600 46 14 32 
Cellular Assembly and Organization 1410 42500 66 22 44 
Cellular Function and Maintenance 1410 47800 95 25 70 
Tissue Morphology 1850 39600 110 36 74 
Organismal Injury and Abnormalities 2000 44300 35 9 26 
Antigen Presentation 2260 46300 36 9 27 
Cell-mediated Immune Response 2260 21800 24 6 18 
Lymphoid Tissue Structure and 
Development 
2260 
46300 54 10 44 
Cell Morphology 3960 35700 33 7 26 
Connective Tissue Development and 
Function 
3960 
39600 41 10 31 
Connective Tissue Disorders 3960 34800 6 0 6 
Digestive System Development and 
Function 
3960 
11400 4 2 2 
Drug Metabolism 3960 34800 9 2 7 
Endocrine System Development and 
Function 
3960 
11400 4 2 2 
Hepatic System Development and 
Function 
3960 
11400 7 2 5 
Hypersensitivity Response 3960 41800 7 2 5 
Nervous System Development and 
Function 
3960 
44300 23 8 15 
Neurological Disease 3960 28700 11 4 7 
Nucleic Acid Metabolism 3960 34800 4 1 3 
Organ Morphology 3960 44300 40 10 30 
Skeletal and Muscular Disorders 3960 21800 14 0 14 
Skeletal and Muscular System 
Development and Function 
3960 
34800 34 14 20 
Cancer 4310 47900 68 20 48 
Respiratory Disease 4770 44300 12 4 8 
Visual System Development and 
Function 
5140 
39600 12 2 10 
Free Radical Scavenging 7060 46300 19 5 14 
Dermatological Diseases and 
Conditions 
7190 
43900 21 8 13 
Immunological Disease 7190 34800 23 7 16 
Reproductive System Development 
and Function 
7780 
44300 18 7 11 
Cardiovascular Disease 8570 47900 33 8 25 
Endocrine System Disorders 9400 47900 14 1 13 
Organismal Functions 10000 32900 7 2 5 
Hair and Skin Development and 
Function 
11400 
11400 2 1 1 
Hepatic System Disease 11400 11400 2 1 1 
Reproductive System Disease 11400 28000 9 1 8 
Infectious Disease 12300 35700 22 6 16 
Protein Synthesis 12400 21800 18 2 16 
Cell Signaling 15700 33500 10 1 9 
Amino Acid Metabolism 21400 33700 11 4 7 
Gene Expression 21500 21500 54 24 30 
Auditory Disease 21800 28700 7 3 4 
Ophthalmic Disease 21800 21800 2 0 2 
Protein Trafficking 21800 21800 2 1 1 
Nutritional Disease 33500 33500 9 2 7 
Post-Translational Modification 33500 33500 9 1 8 
Behavior 33700 33700 6 1 5 
DNA Replication, Recombination, and 
Repair 
34800 
42500 9 6 3 
Renal and Urological System 
Development and Function 
34800 34800 
2 0 2 
Vitamin and Mineral Metabolism 34800 34800 2 0 2 
a Total number of unique genes with transcript levels at significantly higher concentration than 
ground control samples (FDR value at 0.05 and 1.5 fold change). The input for the IPA analysis 
was upregulated genes 607 and downregulated genes 1071 genes.  
b Gene expression data and IPA analysis was subjected to FDR (Benjamini-Holchberg) 
correction. P-value ranges reflect the chance genes have been randomly assigned to a specific 
biological function category using IPA software. 
c Genes may have been assigned to more than one category based on biological function 
classification. The unique upregulated genes were 130 and downregulated genes were 267 
which were classified in the biological functional categories. 
 
Table 4. M-CSF pathway of bone marrow derived macrophages gene regulation 
due to spaceflight 
Gene 
symbol 
Entrez 
gene ID 
Gene name 
p-
valuea 
Fold 
change 
Csf1r 12978 
Colony stimulating factor 1 
receptor 
0.04* -1.6 
Hras1 15461 
Harvey rat sarcoma virus 
oncogene 1 
0.24 -1.3 
Ets1 23871 
E26 avian leukemia oncogene 1, 
5' domain 
0.59  1.3 
Ets2 23872 
E26 avian leukemia oncogene 2, 
3' domain 
0.79  1.1 
Etv3 27049 
ETS-domain transcriptional 
repressor, METS, Pe1 
0.32 -2.0 
Ddx20 53975 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 20, Dp103. 
0.83 -1.1 
Jun 16476 Jun oncogene 0.62  1.3 
Fos 14281 FBJ osteosarcoma oncogene 0.14 -1.9 
Sin3 20467 
Transcriptional regulator, SIN3B 
(yeast) 
0.89 -1.0 
Hdac2 15182 Histone deacetylase 2 0.92  1.0 
Ncord2 20602 Nuclear receptor co-repressor 2 0.37 -1.2 
E2f4 104394 E2F transcription factor 4 0.04* -1.6 
Rbl-1 19650 Retinoblastoma-like 1 (p107) 0.02* -4.4 
Rbl-2 19651 Retinoblastoma-like 2 0.35 -1.4 
Hoxb7 15415 Homeobox B7 0.08  1.1 
Egr1 13653 Early growth response 1 0.03  2.1 
Irf1 16362 Interferon regulatory factor 1 0.79 -1.0 
Chrac1 93696 
Chromatin accessibility complex 
1 
0.50 -1.1 
Hoxb4 15412 Homeobox B4 0.01  1.7 
Hoxb3 15410 homeobox B3 0.03  1.2 
Cebpa 12606 
CCAAT/enhancer binding protein 
(C/EBP), alpha 
0.10 -1.0 
Cebpb 12608 
CCAAT/enhancer binding protein 
(C/EBP), beta 
0.09  1.1 
Cebpg 12611 
CCAAT/enhancer binding protein 
(C/EBP), gamma 
0.69 -1.1 
Gata1 14460 GATA binding protein 1 0.37 -1.5 
Gata2 14461 GATA binding protein 2 0.04* -2.1 
Scly 50880 Selenocysteine lyase 0.38  1.1 
Myb 17863 Myeloblastosis oncogene 0.19  1.8 
Myc 17869 Myelocytomatosis oncogene 0.05 -1.7 
Runx1 12394 Runt related transcription factor 1 0.04* -1.6 
Tnf 21926 Tumor necrosis factor 0.66 -1.1 
Stat3 20848 
signal transducer and activator of 
transcription 3 
0.64 -1.1 
Table
Sfpi1 20375 SFFV proviral integration 1 0.56  1.1 
Zbtb16 235320 
Zinc finger and BTB domain 
containing 16 
0.21  1.2 
a Gene expression data and IPA analysis was subjected to FDR 
(Benjamini-Holchberg) correction with a cut-off value at 0.05. * indicates 
genes below the cut off. 
 
Table 5.  Transcriptional changes in coagulation system components 
Fold 
change 
p-valuea Coagulation components and regulatorsb 
-1.1 NS Factor II, Prothrombin: C 
-1.8 0.04 Factor III, Thromboplastin (Tissue Factor): E 
1.8 NS Factor V, Labile factor (accelerator globulin, accelerin): C 
-1.9 NS Factor VII, Serum (or tissue) prothrombin: E 
-2.5 NS Factor VIII, Anti-hemophilic factor A: I 
-2.7 0.04 Factor IX, Christmas factor: 
-1.5 NS Factor X, Stuart Power factor: C 
1.5 NS Factor XI, Plasma thromboplastin antecedent (PTA): I 
-4.6 NS Factor XII, Hageman factor (contact factor): I 
-1.8 NS Factor XIII, Fibrin-stabilizing factor: C    
-2.9 NS Protein C: I and C 
-2.3 0.04 Protein S: I and C 
-2.1 NS Thrombomodulin: I and C 
-5.0 0.04 Kallekrein B1: I 
-2.4 0.04 Tissue factor pathway inhibitor: E 
-6.5 0.04 Plasmin: F 
-1.5 NS Von Willebrand factor: I and E 
-1.5 NS Plasminogen activator, urokinase: F 
a Gene expression data and IPA analysis was subjected to FDR (Benjamini-
Holchberg) correction. No significant difference (NS), FDR value at 0.05.  
b Components involved in intrinsic (I), extrinsic (E), or common (C) coagulation 
pathways or in fibrinolysis  (F).   
 
 
Table
Table 6. Insulin receptor signaling pathway of bone marrow derived 
macrophages gene regulation due to spaceflight. 
Gene 
symbol 
Entrez 
gene  
ID 
Gene name 
p-
value 
Fold 
change 
Insr  16337 insulin receptor 0.044* -2.01 
Cbl 12402 
Casitas B-lineage 
lymphoma 
0.008* -1.90 
Rhoq  104215 
ras homolog gene family, 
member Q 
0.008 -1.35 
Tsc2  22084 tuberous sclerosis 2 0.044* -2.50 
 Rapgef1 107746 
Rap guanine nucleotide 
exchange factor (GEF) 1 
0.045* -1.61 
Pten  19211 
phosphatase and tensin 
homolog 
0.045* -1.83 
Lipe  16890 lipase, hormone sensitive 0.041* -3.61 
Nck1  17973 
non-catalytic region of 
tyrosine kinase adaptor 
protein 1 
0.048* -1.70 
Gab1 14388 
growth factor receptor 
bound protein 2-associated 
protein 1 
0.048* -2.53 
Ptpn11  19247 
protein tyrosine 
phosphatase, non-receptor 
type 11 
0.076 -1.44 
Foxo4 54601 forkhead box O4 0.101 -3.22 
Sgk1  20393 
serum/glucocorticoid 
regulated kinase 1 
0.127 -1.99 
Socs3  12702 
suppressor of cytokine 
signaling 3 
0.138 2.41 
Stx4a  20909 syntaxin 4A (placental) 0.139 1.09 
Mtor  56717 
mechanistic target of 
rapamycin 
(serine/threonine kinase) 
0.155 -1.31 
Rptor  74370 
regulatory associated 
protein of MTOR, complex 
1 
0.174 -1.66 
Eif4ebp1  13685 
eukaryotic translation 
initiation factor 4E binding 
protein 1 
0.185 -1.25 
Raf1  110157 
v-raf-leukemia viral 
oncogene 1 
0.191 1.67 
Irs1  16367 insulin receptor substrate 1 0.198 -1.55 
Table
Mapk8  26419 
mitogen-activated protein 
kinase 8 
0.257 -1.47 
Ptpn1  19246 
protein tyrosine 
phosphatase, non-receptor 
type 1 
0.289 -1.26 
Foxo3  56484 forkhead box O3 0.298 1.28 
Ptprf  19268 
protein tyrosine 
phosphatase, receptor 
type, F 
0.340 2.08 
Pde3b  18576 
phosphodiesterase 3B, 
cGMP-inhibited 
0.357 1.32 
Stxbp4  20913 syntaxin binding protein 4 0.409 -1.59 
Slc2a4 20528 
solute carrier family 2 
(facilitated glucose 
transporter), member 4 
0.445 1.81 
Vamp2  22318 
vesicle-associated 
membrane protein 2 
0.450 1.24 
Tsc1  64930 tuberous sclerosis 1 0.461 -1.43 
Pdpk1  18607 
3-phosphoinositide 
dependent protein kinase 1 
0.520 -1.30 
Eif4e 13684 
eukaryotic translation 
initiation factor 4E 
0.555 -1.33 
Bad 12015 
BCL2-associated agonist 
of cell death 
0.558 1.20 
Grb2 14784 
growth factor receptor 
bound protein 2 
0.672 -1.10 
Fyn 14360 Fyn proto-oncogene 0.704 -1.13 
Shc1  20416 
src homology 2 domain-
containing transforming 
protein C1 
0.756 1.15 
Acly 104112 ATP citrate lyase 0.889 -1.04 
Grb10 14783 
growth factor receptor 
bound protein 10 
0.917 -1.08 
Trip10 106628 
thyroid hormone receptor 
interactor 10 
0.960 1.02 
Akt1  11651 
thymoma viral proto-
oncogene 1 
0.432 -1.64 
Mapk1  26413 
mitogen-activated protein 
kinase 1 
0.422 -1.65 
Foxo1  56458 forkhead box O1 0.381 -1.15 
Gsk3b  56637 
glycogen synthase kinase 
3 beta 
0.105 -1.57 
Gys1  14936 
glycogen synthase 1, 
muscle 
0.834 1.13 
Irs1 16367 insulin receptor substrate 1 0.198 -1.54 
Jak1  16451 Janus kinase 1 0.075 -1.62 
Map2k1  26395 
mitogen-activated protein 
kinase kinase 1 
0.236 -1.75 
Rps6kb1  72508 
ribosomal protein S6 
kinase, polypeptide 1 
0.220 -1.72 
Pik3r1  18708 
phosphatidylinositol 3-
kinase, regulatory subunit, 
polypeptide 1 (p85 alpha) 
0.051 -1.84 
Prkaca  18747 
protein kinase, cAMP 
dependent, catalytic, alpha 
0.657 1.05 
Prkcz  18762 protein kinase C, zeta 0.772 -1.22 
Ppp1cc  19047 
protein phosphatase 1, 
catalytic subunit, gamma 
isoform 
0.096 -1.15 
Rasa1  218397 
RAS p21 protein activator 
1 
0.239 -1.57 
Inpp5d  16331 
inositol polyphosphate-5-
phosphatase D 
0.149 -1.27 
Kcnj8 16523 
potassium inwardly-
rectifying channel, 
subfamily J, member 8 
0.298 1.36 
a Gene expression data and IPA analysis were subjected to FDR 
(Benjamini-Holchberg) correction. * indicates genes below the 0.05 cut 
off.  
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